| methylprednisolone sodium succinate / Generic mfg. |
Ocarina II, NCT05232825 / 2020-005448-48: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis |
|
|
| Active, not recruiting | 3 | 236 | Europe, US, RoW | Ocrelizumab IV, RO4964913, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally | Hoffmann-La Roche | Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | 04/25 | 04/25 | | |
|
|
MPIV, NCT03876444: Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms |
|
|
| Recruiting | 2/3 | 128 | RoW | Intravenous Methylprednisolone, Oral Pednisolone | Suvasini Sharma | Infantile Spasm | 04/22 | 10/22 | | |
| Not yet recruiting | 2 | 20 | | | St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney | Neuromyelitis Optica, Stiff Person Syndrome, Myasthenia Gravis, Central Nervous System Vasculitis | | | | |
ACTRN12619000348156: Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis. |
|
|
| Recruiting | 2 | 50 | | | Alfred Health, Alfred Health | Relapsing Remitting Multiple Sclerosis | | | | |
ACTRN12616000151437: A Phase II study:
Haematopoietic Stem Cell Transplantation for highly active
treatment resistant multiple sclerosis .
|
|
|
| Recruiting | 2 | 20 | | | Austin Health, Austin Health | Relapsing Remitting Multiple Sclerosis | | | | |
| Recruiting | 2 | 30 | | | St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney | Multiple Sclerosis | | | | |
2010-023560-40: Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed. Blodstamcellstransplantation för patienter med skovvis förlöpande MS (multipel sklerosis), där standardbehandling givit otillräcklig effekt. |
|
|
| Ongoing | 2 | 120 | Europe | , Powder for solution for injection, Powder for infusion*, Solution for injection, Powder and solvent for dispersion for injection, Tysabri, Sendoxan, Thymoglobuline, Neupogen, Solu-Medrol | Uppsala l�ns landsting | Relapsing-remitting multiple sclerosis | | | | |
| Ongoing | 2 | 200 | Europe | Solu-Medrol, Film-coated tablet, Injection, Solu-Medrol | Department of Clinical Neuroscience, Karolinska Institutet, Vetenskapsrådet | Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapse, Patients with Multiple Sclerosis (MS) with a relapse or with symptoms and signs giving rise to high suspicion of MS with relapse, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 2 | 158 | Europe | Methylprednisolone, Solu-Medrol, Isotonic saline, Placebo | Christian Hassager | Out-Of-Hospital Cardiac Arrest, Cardiac Arrest, Cardiac Arrest With Successful Resuscitation, Post Cardiac Arrest Syndrome, Systemic Inflammatory Response Syndrome, Neurological Injury | 07/22 | 02/23 | | |
| Recruiting | 2 | 200 | Europe | Imatinib Mesylate, Methylprednisolone | Tomas Olsson, The Swedish Research Council | Multiple Sclerosis | 12/22 | 07/23 | | |
IN-DXM-EMRR, NCT06223074: Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration |
|
|
| Enrolling by invitation | 2 | 80 | RoW | IV Methylprednisolone administration, ST, Nasal Methylprednisolone (MT), Nasal MT | Universidad Nacional Autonoma de Mexico, Instituto Nacional de Neurología y Neurocirugía | Methylprednisolone, Intranasal Administration, Patients With an Active Multiple Sclerosis Relapse | 11/24 | 02/25 | | |
2020-000855-11: USING STEROID TREATMENT TO INHIBIT INFLAMMATION AND BRAIN INJURY IN PATIENTS RESUSCITATED FROM CARDIAC ARREST. BRUG AF STEROIDBEHANDLING TIL AT MINDSKE INFLAMMATION OG HJERNESKADE I GENOPLIVEDE HJERTESTOPSPATIENTER. |
|
|
| Not yet recruiting | 2 | 120 | Europe | Solu-medrol, 6132, Solution for injection, Solu-Medrol | Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen University Hospital Rigshospitalet | We investigate the efficacy of commercially available glucocorticoid "methylprednisolone" (Solu-Medrol) for reducing the systemic inflammatory response and neurological injury in patients resuscitated after out-of-hospital cardiac arrest. Vi undersøger den antiinflammatoriske og neuroprotektive effekt af det kommercielt tilgængelige glukokortikoid "methylprednisolon" (Solu-Medrol) i patienter genoplivet efter hjertestop uden for hospital., Patients resuscitated from out-of-hospital cardiac arrest have a high mortality due to a systemic inflammatory response and severe brain injury. We hope that Solu-Medrol can prevent this response. Patienter genoplivet efter hjertestop uden for hospital har en høj dødelighed grundet et inflammatorisk respons og svær hjerneskade. Vi håber at Solu-Medrol kan modvirke dette respons., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 2 | 60 | US | Bupivacaine HCl 0.5% Injectable Solution, Methylprednisolone 40 MG Injection | Mayo Clinic | Episodic Migraine | 02/25 | 07/25 | | |
| Not yet recruiting | 2 | 230 | US | Lidocaine hydrochloride, lidocaine, Xylocaine-MPF, Methylprednisolone sodium succinate, methylprednisolone, SOLU-MEDROL, Standard of Care | The Cooper Health System | Refractory Migraine | 03/27 | 03/27 | | |
| Recruiting | 2 | 163 | US | High-dose methylprednisolone, Solu-Medrol, Equine anti-thymocyte globulin, ATGAM, Prednisolone, 15 mg/mL oral solution National Drug Code: 62135-250-37, Placebo for prednisolone, Placebo for infusions, 0.9% Sodium chloride, Diphenhydramine, Benadryl, Methylprednisolone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ann & Robert H Lurie Children's Hospital of Chicago | Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation | 01/26 | 01/27 | | |
Ra-P-OCD, NCT04323566: Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement |
|
|
| Enrolling by invitation | 2 | 40 | Europe | Rituximab | Uppsala University Hospital, Uppsala University | Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder, Brief Psychotic Disorder, Schizo Affective Disorder, Other Psychoses, Unspecified Psychosis | 04/26 | 05/26 | | |
NCT02784210: Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques |
|
|
| Recruiting | 2 | 30 | US | Methylprednisolone, Prednisone | National Institute of Neurological Disorders and Stroke (NINDS) | Multiple Sclerosis | 12/28 | 12/28 | | |
ACTRN12622001186741: Autologous Stem Cell Transplant in Neuro-Inflammatory diseases other than multiple sclerosis |
|
|
| Not yet recruiting | N/A | 5 | | | The Alfred- Melbourne, The Alfred-Melbourne | Neuro-Inflammatory disease | | | | |
NCT06068829: Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 80 | NA | Inebilizumab, Rituximab(RTX) | Feng Jinzhou | Neuromyelitis Optica Spectrum Disorders | 06/24 | 06/25 | | |
NCT06118398: Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 24 | NA | Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP | Feng Jinzhou | Neuromyelitis Optica, Efgartigimod | 11/24 | 05/25 | | |
NCT05891379: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 50 | NA | Inebilizumab, oral immunosuppressant | Xuanwu Hospital, Beijing, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 07/25 | 07/25 | | |
